BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30981462)

  • 1. [Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines].
    Castinetti F; Borson-Chazot F
    Bull Cancer; 2019 May; 106(5):492-496. PubMed ID: 30981462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. French Endocrine Society Guidance on endocrine side effects of immunotherapy.
    Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
    Endocr Relat Cancer; 2019 Feb; 26(2):G1-G18. PubMed ID: 30400055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary and adrenal disorders induced by immune checkpoint inhibitors.
    Albarel F; Brue T; Castinetti F
    Ann Endocrinol (Paris); 2023 May; 84(3):339-345. PubMed ID: 36965852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
    Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
    Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
    Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Endocrinopathies induced by immune checkpoint inhibitors].
    Jaafar J; Mavromati M; Philippe J
    Rev Med Suisse; 2018 Jan; 14(588-589):34-38. PubMed ID: 29337446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY.
    Coniac S; Stoian M
    Acta Endocrinol (Buchar); 2021; 17(2):286-289. PubMed ID: 34925584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we treat endocrine complications of immune checkpoint inhibitors.
    Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
    ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to expert opinion on endocrine complications of new anticancer therapies.
    Castinetti F; Borson-Chazot F
    Ann Endocrinol (Paris); 2018 Oct; 79(5):535-538. PubMed ID: 30056976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions.
    Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
    Ann Endocrinol (Paris); 2018 Oct; 79(5):591-595. PubMed ID: 30056975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine side effects of cancer immunotherapy.
    Cukier P; Santini FC; Scaranti M; Hoff AO
    Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine dysfunction following immune checkpoint inhibitor therapy.
    Konda B; Nabhan F; Shah MH
    Curr Opin Endocrinol Diabetes Obes; 2017 Oct; 24(5):337-347. PubMed ID: 28661915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach.
    Iglesias P
    Eur J Intern Med; 2018 Jan; 47():6-13. PubMed ID: 28826822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis.
    Albarel F; Castinetti F; Brue T
    Eur J Endocrinol; 2019 Sep; 181(3):R107-R118. PubMed ID: 31311002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
    Stelmachowska-Banaƛ M; Czajka-Oraniec I
    Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality imaging of endocrine immune related adverse events: a primer for radiologists.
    Alessandrino F; Shah HJ; Ramaiya NH
    Clin Imaging; 2018; 50():96-103. PubMed ID: 29348053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy.
    Higham CE; Olsson-Brown A; Carroll P; Cooksley T; Larkin J; Lorigan P; Morganstein D; Trainer PJ;
    Endocr Connect; 2018 Jul; 7(7):G1-G7. PubMed ID: 29930025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy.
    Atkinson M; Lansdown AJ
    Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101635. PubMed ID: 35382989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.